Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weese, W. C.
Right arrow Articles by Kazemi, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weese, W. C.
Right arrow Articles by Kazemi, H.

Chest, Vol 67, 57-60, Copyright © 1975 by American College of Chest Physicians

ARTICLES

Interstitial lung disease resistant to corticosteroid therapy. Report of three cases treated with azathioprine or cyclophosphamide

WC Weese, BW Levine and H Kazemi

Three patients with severe progressive interstitial lung disease refractory to steroid therapy were treated with immunosuppressive drugs. Biopsy material of one showed mainly fibrosis, while that of the second showed interstitial pneumonitis as well; both patients received azathioprine. Cyclophosphamide was employed in the third patient with systemic vasculitis and massive hemoptysis. All patients had reduced lung volumes and abnormal gas exchange, which continued to worsen on high doses of steroids. In patients 1 and 2, there was long-term stabilization of lung function, while pulmonary physiologic abnormalities in the patient with vasculitis reverted to normal on five months of cyclophosphamide. Although the etiology of most forms of interstitial lung disease is unknown, several reports suggest at least a partial immunologic basis. Abatement in progression of disease in this small series would suggest that a trial of immunosuppressive drugs be considered in interstitial lung disease when steroid therapy fails.


This article has been cited by other articles:


Home page
 Eur Respir JHome page
D. Bouros and K. M. Antoniou
Current and future therapeutic approaches in idiopathic pulmonary fibrosis
Eur. Respir. J., October 1, 2005; 26(4): 693 - 703.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. A. Zisman, J. P. Lynch III, G. B. Toews, E. A. Kazerooni, A. Flint, and F. J. Martinez
Cyclophosphamide in the Treatment of Idiopathic Pulmonary Fibrosis : A Prospective Study in Patients Who Failed To Respond to Corticosteroids
Chest, June 1, 2000; 117(6): 1619 - 1626.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
D. M Mitchell and A. Woodcock
Introduction
Thorax, August 1, 1999; 54(90002): S1 - 1.
[PDF]

Home page
 ThoraxHome page
B. T. SOCIETY and S. O. C. COMMITTEE
The Diagnosis, Assessment and Treatment of Diffuse Parenchymal Lung Disease in Adults---British Thoracic Society recommendations
Thorax, April 1, 1990; 54(90001): 1S - 28.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1975 by the American College of Chest Physicians.